entertainment -WSS

entertainment

author：fashion 2025-09-29 13:46:19 - browse：8227

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Results on Novartis prostate cancer therapy could expand its use

WSS

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Readout LOUD podcast: Live from the 2023 STAT Summit

Smaller biotechs seek to piggyback on weight loss drug boom

Why a market frenzy over new weight loss drugs defies logic

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

FDA clears Verve to begin U.S. study of gene

hotspot

entertainment

hotspot

How to save PrEP access — and even expand it

STAT Summit: Meghan O’Rourke on making chronic illness visible

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT Summit: Meghan O’Rourke on making chronic illness visible

The high cost of giving birth even with insurance

Is there really a nursing shortage in the U.S.?

What does generative AI mean for health care? We asked experts

STAT Summit: Meghan O’Rourke on making chronic illness visible

Medical records are filled with copy

J&J lung cancer data amount to new salvo against AstraZeneca

hotspot

STAT Readout: Friday, Oct. 20 biotech updates

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Readout LOUD podcast: Live from the 2023 STAT Summit

STAT Readout Newsletter: Biotech news today

Study on Amgen’s bispecific immunotherapy produces positive data

UnitedHealth, Optum discontinue NaviHealth name

hotspot

knowledge

leisure time

hotspot